(IN BRIEF) A landmark international study has provided robust evidence that elevated levels of prolactin, a hormone involved in breast development, increase the risk of breast cancer in post-menopausal women. Researchers from The Institute of Cancer Research in London, along … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged B2Risk consortium, BMI, breast cancer, Breast Cancer Now, cohort studies, Dr Simon Vincent, early diagnosis, ICR, Institute of Cancer Research, invasive breast cancer, mammographic density, personalized prevention, plasma levels, PMH, polygenic risk score, post-menopausal, Professor Montse Garcia-Closas, prolactin, risk factor, targeted interventions
(IN BRIEF) A groundbreaking AI-powered research platform, POETIC-AI, has been unveiled by scientists from The Institute of Cancer Research, promising to accelerate cancer biomarker discovery. Demonstrated at The Alan Turing Institute’s fifth AI UK conference, the platform integrates diverse clinical … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged artificial intelligence, biomarkers, cancer research, Cancer Research UK, clinical trial data, Collaborative Research, CT, digital pathology, Dr. Ferran Cardo, Dr. Maggie Cheang, hormone therapy, ICR, Integrated Discovery and Diagnostics programme, Ki67, medical imaging, MRI, natural language AI, Palantir Foundry, POETIC trial, POETIC-AI, Professor Manuel Salto-Tellez, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Xixuan Zhu
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
(IN BRIEF) Researchers from The Institute of Cancer Research, London, and Barts Cancer Institute have discovered how the extracellular matrix (ECM) surrounding tumours influences cancer cells to become aggressive and spread throughout the body. Their study, published in Nature Communications, … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged Barts Cancer Institute, breast cancer, cancer metastasis, cancer research, Cancer Therapies, cancer treatment, early cancer detection, ECM, extracellular matrix, ICR, lysyl oxidase, melanoma, metastasis, metastasis prevention, Nature Communications, tumor behavior, tumor biology
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?